دورية أكاديمية

Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review

التفاصيل البيبلوغرافية
العنوان: Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review
المؤلفون: ter Maat, Laurens S., van Duin, Isabella A.J., Elias, Sjoerd G., van Diest, Paul J., Pluim, Josien P.W., Verhoeff, Joost J.C., de Jong, Pim A., Leiner, Tim, Veta, Mitko, Suijkerbuijk, Karijn P.M.
المصدر: ter Maat , L S , van Duin , I A J , Elias , S G , van Diest , P J , Pluim , J P W , Verhoeff , J J C , de Jong , P A , Leiner , T , Veta , M & Suijkerbuijk , K P M 2022 , ' Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review ' , European Journal of Cancer , vol. 175 , pp. 60-76 . https://doi.org/10.1016/j.ejca.2022.07.034Test
سنة النشر: 2022
مصطلحات موضوعية: Biomarkers, Deep learning, Imaging, Immune checkpoint inhibitors, Immunotherapy, Machine learning, Magnetic resonance imaging, Positron-emission tomography, Prognosis, Tomography, x-ray computed, /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, name=SDG 3 - Good Health and Well-being
الوصف: Background: Checkpoint inhibition has radically improved the perspective for patients with metastatic cancer, but predicting who will not respond with high certainty remains difficult. Imaging-derived biomarkers may be able to provide additional insights into the heterogeneity in tumour response between patients. In this systematic review, we aimed to summarise and qualitatively assess the current evidence on imaging biomarkers that predict response and survival in patients treated with checkpoint inhibitors in all cancer types. Methods: PubMed and Embase were searched from database inception to 29th November 2021. Articles eligible for inclusion described baseline imaging predictive factors, radiomics and/or imaging machine learning models for predicting response and survival in patients with any kind of malignancy treated with checkpoint inhibitors. Risk of bias was assessed using the QUIPS and PROBAST tools and data was extracted. Results: In total, 119 studies including 15,580 patients were selected. Of these studies, 73 investigated simple imaging factors. 45 studies investigated radiomic features or deep learning models. Predictors of worse survival were (i) higher tumour burden, (ii) presence of liver metastases, (iii) less subcutaneous adipose tissue, (iv) less dense muscle and (v) presence of symptomatic brain metastases. Hazard rate ratios did not exceed 2.00 for any predictor in the larger and higher quality studies. The added value of baseline fluorodeoxyglucose positron emission tomography parameters in predicting response to treatment was limited. Pilot studies of radioactive drug tracer imaging showed promising results. Reports on radiomics were almost unanimously positive, but numerous methodological concerns exist. Conclusions: There is well-supported evidence for several imaging biomarkers that can be used in clinical decision making. Further research, however, is needed into biomarkers that can more accurately identify which patients who will not benefit from checkpoint inhibition. Radiomics ...
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: English
العلاقة: https://research.tue.nl/en/publications/5bbf4821-e4a5-4aa2-9134-2b5b26abfbccTest
DOI: 10.1016/j.ejca.2022.07.034
الإتاحة: https://doi.org/10.1016/j.ejca.2022.07.034Test
https://research.tue.nl/en/publications/5bbf4821-e4a5-4aa2-9134-2b5b26abfbccTest
https://pure.tue.nl/ws/files/250667950/1_s2.0_S0959804922004798_main.pdfTest
http://www.scopus.com/inward/record.url?scp=85139737645&partnerID=8YFLogxKTest
حقوق: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.CEE679A
قاعدة البيانات: BASE